Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis

X
Trial Profile

A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Alzheimer's disease; Delusions; Frontotemporal dementia; Hallucinations; Lewy body disease; Parkinson's disease; Vascular dementia
  • Focus Registrational; Therapeutic Use
  • Acronyms ACP-103-045; HARMONY
  • Sponsors Acadia Pharmaceuticals
  • Most Recent Events

    • 01 Feb 2024 Results of subgroup analysis assessing the effect of pimavanserin on psychosis in the PD dementia, published in the Parkinsonism and Related Disorders
    • 18 Sep 2022 Results of pooled analysis of 3 6-week studies (012, 014, and 020) and subgroup of PD dementia (PDD) patients from HARMONY assessing motor and cognition-related safety in pimavanserin-treated patients with Parkinson's Disease Psychosis, presented at the 26th International Congress of Parkinson's Disease and Movement Disorders.
    • 04 Aug 2022 Results of post-hoc sub-group analysis assessing efficacy and safety of pimavanserin in patients with Alzheimer's dementia psychosis, presented at the Alzheimer's Association International Conference 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top